An Open-Label, Two-Period, Two-Sequence, Two-Treatment Randomized, Single Oral Dose, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetic Profile of VHX-896 in Healthy Volunteers
Latest Information Update: 04 Feb 2025
Price :
$35 *
At a glance
- Drugs VHX-896 (Primary)
- Indications Bipolar disorders; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Vanda Pharmaceuticals
- 04 Feb 2025 New trial record